Related Experiment Video
Updated: Jun 12, 2025
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
10.8K
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Stéphanie Gaillard1, Christina Lacchetti2, Deborah K Armstrong1
1Johns Hopkins University, Baltimore, MD.
Summary
Updated guidelines recommend evaluating stage III-IV epithelial ovarian cancer (EOC) patients with imaging and genetic testing. Treatment decisions for advanced EOC balance primary cytoreductive surgery (PCS) with neoadjuvant chemotherapy (NACT) based on surgical candidacy and predicted outcomes.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Genetics
Background:
- Epithelial ovarian cancer (EOC) staging impacts treatment strategies.
- Neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) are key treatment modalities for advanced EOC.
Purpose of the Study:
- To provide updated clinical guidance for NACT and PCS in stage III-IV EOC.
- To establish evidence-based recommendations for managing advanced ovarian cancer.
Main Methods:
- Systematic review updated by a multidisciplinary Expert Panel.
- Evidence base comprises sixty-one studies.
Main Results:
- Recommendations cover initial evaluation, genetic testing, and surgical vs. chemotherapy approaches.
- Specific guidance is provided for NACT regimens, timing of interval surgery, and post-surgery treatment.
Conclusions:
- Patients with suspected advanced EOC require comprehensive evaluation including imaging and genetic profiling.
- Treatment selection between PCS and NACT depends on patient fitness, likelihood of complete cytoreduction, and perioperative risk.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
153
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
153
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
236
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
236
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K